Skip to Content

Protagenic Therapeutics Inc PTIX

Morningstar Rating
$1.55 −0.02 (0.96%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PTIX is trading at a 654% premium.
Price
$1.58
Fair Value
$4.39
Uncertainty
Extreme
1-Star Price
$61.32
5-Star Price
$2.84
Economic Moat
Qfcrk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTIX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.56
Day Range
$1.471.68
52-Week Range
$0.682.23
Bid/Ask
$1.46 / $1.63
Market Cap
$6.85 Mil
Volume/Avg
11,088 / 16,430

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
3

Valuation

Metric
PTIX
Price/Earnings (Normalized)
Price/Book Value
3.74
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
PTIX
Quick Ratio
6.19
Current Ratio
6.41
Interest Coverage
−47.89
Quick Ratio
PTIX

Profitability

Metric
PTIX
Return on Assets (Normalized)
−87.65%
Return on Equity (Normalized)
−108.33%
Return on Invested Capital (Normalized)
−105.90%
Return on Assets
PTIX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSdzybchbwVfht$595.6 Bil
VRTX
Vertex Pharmaceuticals IncKbwrnptkYldsny$117.9 Bil
REGN
Regeneron Pharmaceuticals IncKnwlxzwgTfcwsk$108.5 Bil
MRNA
Moderna IncWyqfgzvwGvfs$63.9 Bil
BNTX
BioNTech SE ADRQwymjrltmDdcq$23.4 Bil
ARGX
argenx SE ADRFlwbkcwpdVnnzs$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncPglhlhbdnXkpcknk$18.7 Bil
BMRN
Biomarin Pharmaceutical IncVzlvsprNccgqbc$14.3 Bil
INCY
Incyte CorpQxwctqjlXpctf$12.9 Bil
UTHR
United Therapeutics CorpCqmrcxjZnp$12.1 Bil

Sponsor Center